Keanrui Pharmaceutical Inc. (Keanrui Pharma for short) was registered in Massachusetts, USA, On October 8 2019, with Nanjing Meirui Pharmaceutical Co., Ltd as the main investor. It means that Trade Star Pharmaceutical Holding Group had set up a subsidiary in the United States , marking a further step on the oversea business of Trade Star Group.

    The core members from Keanrui Pharma (such as executive directors, CEO, etc.) have more than 20 years of experience in pharmaceutical industry, they used to serve as research scientists, quality and regulatory directors, general managers, etc. in world well-known pharmaceutical companies such as Novartis. These members have a deep understanding of entire process of R&D, production, registration and sales of new drugs and generic drugs in the United States.They also have established wide connections with entrepreneurs, scientists, and investors in the pharmaceutical industry in US. They can grasp the trends of development and have the insight into the growth points of the pharmaceutical industry. It will provide a guarantee for the project introducting, technology transfering, quality system improving and product exporting for Keanrui Pharma and its parent company, Nanjing Meirui Pharmaceutical Co., successfully with GMP management and operation experience.

    The United States is in a leading position in the R&D of innovative drugs. The excellent technological capabilities of pharmaceutical production and the globally recognized pharmaceutical regulatory standards from long-term practice, making the United States as a pharmaceutical powerhouse worldwide. However, high cost of pharmaceutical innovation and high medical price and expense in the United States also make it necessary to import high-quality, low-cost generic drugs to reduce the burden on U.S. health insurance. The cooperation between Chinese and American pharmaceutical companies will be much more complementary. Keanrui Pharma will make the connection and the cooperation between the international pharmaceutical companies, continuously learning the advanced technology and new management concept from them, and importing advanced technology and products into chinese market from American counterparts. At the same time, according to the FDA's registration regulation and policies, we will apply for the drugs in US and China at sametime and export these drugs to the United States from China, exploring the American markets, implementing the company`s strategic of "introducing in and going out" , providing strategic support for the enterprise development, and catching the development opportunities up in the US.